Policy & Regulation
Koselugo approved in Canada for adults with NF1 and inoperable plexiform neurofibromas
...
Bristol Myers Squibb reports positive Phase 3 results for oral mezigdomide in multiple myeloma
9 March 2026 - Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) on Monday announced positive interim Phase 3 results from the SUCCESSOR-2 study evaluating oral mezigdomide in combination with...
Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis
9 March 2026 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) on Monday reported positive topline results from a Phase 2 study evaluating tilrekimig (PF-07275315) in adults with moderate to severe...
Agilent to acquire Biocare Medical for USD950m to expand pathology portfolio
9 March 2026 - Agilent Technologies Inc (NYSE:A), a provider of analytical and clinical laboratory technologies, said on Monday that it has agreed to acquire clinical pathology specialist Biocare Medi...
AstraZeneca and Daiichi Sankyo's Enhertu receives US priority review for post-neoadjuvant HER2-positive early breast cancer
9 March 2026 - British-Swedish biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) and Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Monday that the ...
Ipsen withdraws tazverik across all markets following safety concerns in lymphoma trial
9 March 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Monday the voluntary withdrawal of Tazverik (tazemetostat) in all indications from all markets based...